{
    "N/R/U": null,
    "Applicant": "AstraZeneca AB",
    "BLA Number": "761289",
    "Proprietary Name": "Imjudo",
    "Proper Name": "tremelimumab-actl",
    "BLA Type": "351(a)",
    "Strength": "25MG/1.25ML (20MG/ML)",
    "Dosage Form": "Injection ",
    "Route of Administration": "Intravenous",
    "Product Presentation": "Single-Dose Vial",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "October 21, 2022",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": null,
    "Submission Type": "Original",
    "License Number": "2059",
    "Product Number": "001",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": "October 21, 2029"
}